← Back to Screener
Molecular Partners AG American Depositary Shares (MOLN)
Price$4.10
Value ScoreB
Growth ScoreF
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-10.84%
Price vs S&P 500 (4W)-7.40%
VGM Score37.07
Market Capitalization$154.65M
All Metrics
Book Value / Share (Quarterly)$2.30
P/TBV (Annual)1.70x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-20.13%
Cash Flow / Share (Quarterly)$-2.22
Price vs S&P 500 (YTD)-18.62%
Net Profit Margin (TTM)-866.56%
EPS (TTM)$-2.54
10-Day Avg Trading Volume0.02M
EPS Excl Extra (TTM)$-2.54
Revenue Growth (5Y)-24.59%
EPS (Annual)$-2.08
ROI (Annual)-73.41%
Gross Margin (Annual)99.80%
Net Profit Margin (5Y Avg)-646.31%
Cash / Share (Quarterly)$2.65
ROA (Last FY)-60.38%
EBITD / Share (TTM)$-2.34
ROE (5Y Avg)-31.87%
Operating Margin (TTM)-896.17%
Cash Flow / Share (Annual)$-1.75
P/B Ratio1.79x
P/B Ratio (Quarterly)1.84x
Net Income / Employee (Annual)$-521,387
EV / Revenue (TTM)7.24x
Net Interest Coverage (TTM)-16.57x
ROA (TTM)-70.20%
EV / EBITDA (TTM)0.24x
EPS Incl Extra (Annual)$-2.08
Current Ratio (Annual)8.79x
Quick Ratio (Quarterly)9.21x
3-Month Avg Trading Volume0.03M
52-Week Price Return-4.15%
EV / Free Cash Flow (Annual)-0.88x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.30
P/S Ratio (Annual)24.70x
Asset Turnover (Annual)0.03x
52-Week High$3.96
Operating Margin (5Y Avg)-662.57%
EPS Excl Extra (Annual)$-2.08
CapEx CAGR (5Y)-15.76%
Tangible BV CAGR (5Y)-5.55%
26-Week Price Return-2.91%
Quick Ratio (Annual)8.61x
13-Week Price Return-23.86%
Total Debt / Equity (Annual)0.05x
Current Ratio (Quarterly)9.42x
Enterprise Value$77.91M
Revenue / Share Growth (5Y)-31.27%
Asset Turnover (TTM)0.05x
Book Value / Share Growth (5Y)-10.21%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1087.34%
Cash / Share (Annual)$3.13
3-Month Return Std Dev68.01%
Gross Margin (5Y Avg)98.50%
Net Income / Employee (TTM)$-632,518
ROE (Last FY)-76.74%
Net Interest Coverage (Annual)-12.36x
EPS Basic Excl Extra (Annual)$-2.08
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.05x
EPS Incl Extra (TTM)$-2.54
Receivables Turnover (Annual)0.00x
ROI (TTM)-82.80%
P/S Ratio (TTM)14.37x
Pretax Margin (5Y Avg)-646.32%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.71
Price vs S&P 500 (52W)-28.52%
Year-to-Date Return-11.37%
5-Day Price Return-5.36%
EPS Normalized (Annual)$-2.08
ROA (5Y Avg)-23.54%
Net Profit Margin (Annual)-1087.38%
Month-to-Date Return-4.46%
Cash Flow / Share (TTM)$-1.14
EBITD / Share (Annual)$-1.89
Operating Margin (Annual)-1231.73%
LT Debt / Equity (Annual)1.55x
ROI (5Y Avg)-30.50%
LT Debt / Equity (Quarterly)1.48x
EPS Basic Excl Extra (TTM)$-2.54
P/TBV (Quarterly)1.84x
P/B Ratio (Annual)1.70x
Pretax Margin (TTM)-866.56%
Book Value / Share (Annual)$2.71
Price vs S&P 500 (13W)-32.11%
Beta0.42x
P/FCF (Annual)1.05x
Revenue / Share (TTM)$0.00
ROE (TTM)-85.24%
52-Week Low$2.66
vGradeB
gGradeF
mGradeD
vgmGradeD
Show chart for
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.10
4.10
4.10
4.10
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MOLNMolecular Partners AG American Depositary Shares | B | F | D | $4.10 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Molecular Partners AG is a clinical-stage biopharmaceutical company developing DARPin therapeutics—protein-based drugs targeting serious diseases across three main pipeline areas: oncology, ophthalmology, and immuno-oncology. The company's ophthalmology programs focus on retinal diseases including wet age-related macular degeneration and diabetic macular edema, while its oncology candidates employ novel multi-DARPin compounds with differentiated mechanisms of action. With oncology as its primary therapeutic focus, Molecular Partners advances a pipeline of DARPin-based treatments designed to address significant medical needs in cancer and sight-threatening disorders.